• If you are wondering whether Stryker at around US$314 per share still offers value, it helps to separate the headline share price from what the underlying business may be worth.
• Over shorter periods the stock has been strong, with returns of 7.1% over the last week and 10.0% over the last month, but the year-to-date return has declined 9.8% and the 1-year return is down 17.7%. This may change how you think about both opportunity and risk.
• Recent coverage has focused on Stryker's position in the medical equipment space and how investors are reacting to sector-wide themes around healthcare demand and capital spending. This context helps explain why the stock has seen both periods of enthusiasm and pullbacks over the past year as sentiment around the sector has shifted.
• On Simply Wall St's valuation checks, Stryker scores 2 out of 6. The next step is to compare what different valuation methods say about the stock, then look at an even more complete way to think about value that ties the numbers back to the broader investment story.

Stryker scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Stryker Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes a series of future cash flow projections and discounts them back into today’s dollars to estimate what the entire business might be worth right now.

For Stryker, the model used is a 2 Stage Free Cash Flow to Equity approach. The company’s latest twelve month free cash flow is about $4.6b. Analyst based projections and Simply Wall St extrapolations point to free cash flow reaching about $8.5b in 2035, with interim estimates such as $3.7b in 2026, $4.9b in 2027 and $5.7b in 2028, all in $.

When these projected cash flows are discounted back, the DCF model arrives at an estimated intrinsic value of about $375 per share. Compared with a current share price around $314, this implies the stock trades at approximately a 16.3% discount to this DCF based estimate. This indicates that the shares appear undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Stryker is undervalued by 16.3%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Stryker Price vs Earnings (P/E)

For a profitable company, the P/E ratio is a straightforward way to connect what you pay for each share with the earnings that support it. You can think of it as the price tag on each dollar of profit.

What counts as a “normal” P/E depends a lot on how quickly earnings are expected to grow and how risky those earnings are. Higher expected growth and lower perceived risk often justify a higher P/E, while slower growth or higher risk usually point to a lower one.

Stryker currently trades on a P/E of 36.07x. That sits above both the Medical Equipment industry average of 25.44x and a peer group average of 29.62x. To refine this, Simply Wall St uses a proprietary “Fair Ratio”, which estimates what Stryker’s P/E might be given factors such as its earnings profile, industry, profit margins, market cap and key risks. For Stryker, this Fair Ratio is 30.91x.

This Fair Ratio is more tailored than a simple peer or industry comparison because it incorporates company specific characteristics rather than treating all stocks as interchangeable. Comparing the Fair Ratio of 30.91x to the current P/E of 36.07x suggests the stock trades above this fair value estimate.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Stryker Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as your way to attach a clear story about Stryker to hard numbers like your own fair value, revenue, earnings and margin assumptions. Simply Wall St’s Community page lets you pick or create a Narrative, link that story to a forecast and a fair value, then compare it with the current price to help decide if the stock looks attractive or expensive. The platform keeps updating those Narratives as fresh news or earnings arrive. A more optimistic Stryker Narrative that leans toward the higher analyst price target of US$465 and stronger long term earnings expectations will naturally differ from a cautious view that sits closer to US$315, and that spread shows how different perspectives on the same company can translate into very different fair values and decisions about when to act.

Do you think there's more to the story for Stryker? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.